Table 6.
Examples of Ovarian Tumor Odds
| Gene | Change | Odds
|
Combined Odds | Odds, No LOH | Interpretation | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| LOH | A-GVGD/ Mutation | In Trans | Stage | Grade | Histology | Age | |||||
| BRCA1 | 1135insA* | 4.45 | 1,000 | 1 | 1 | 1.33 | 1.47 | 11.8 | 102,662.3 | 23,070.2 | D |
| BRCA1 | P334L | 4.45 | 0.01 | 0.0001 | 1 | 1 | 1 | 7.06 | 0.0000314 | 0.0000071 | N† |
| BRCA2 | 7297delCT | 0.428 | 1,000 | 1 | 1 | 1.61 | 1.76 | 0.52 | 630.65 | 1,473.47 | D |
| BRCA2 | M784V | 0.067 | 0.01 | 1 | 2.05 | 1.61 | 1 | 4.05 | 0.009 | 0.1337 | SN |
| BRCA2 | V1643A | 4.6 | 0.01 | 1 | 2.05 | 1 | 1.76 | 7.92 | 1.3145 | 0.2858 | U |
NOTE. Examples of odds generated from phenotypes listed in Table 4 are shown. The final odds are calculated by combining odds for each of the independent variables. The full list of odds from all sequence alterations and ovarian tumors studied is provided in Appendix Table A5.
Abbreviations: LOH, loss of heterozygosity; A-GVGD, align grantham variation, grantham deviation; D, deleterious; N, neutral; SN, suspected neutral; U, uncertain.
*
Change was also seen in a different individual with breast cancer.
†
Reclassified as neutral by other studies.